Compare

Accustem Sciences Inc. vs Semnur Pharmaceuticals, Inc. vs Aspire Biopharma Holdings, Inc. vs Alzamend Neuro, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Accustem Sciences Inc. ACUT	Semnur Pharmaceuticals, Inc. SMNR	Aspire Biopharma Holdings, Inc. ASBP	Alzamend Neuro, Inc. ALZN
Year ended	2025-12-31	2025-12-31	2025-12-31	2026-04-30
Revenue	n/a	n/a	$6.2K	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	-1.9%	n/a
Operating margin	n/a	n/a	n/m	n/a
Net margin	n/a	n/a	n/m	n/a
Net income	-$1.76M	-$160.42M	-$24.48M	-$8.77M
EPS (Diluted)	-$0.12	-$0.78	-$16.38	-$2.63
Operating cash flow	-$850.4K	-$5.87M	-$4.92M	-$8.07M
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	n/a	$20.0K	n/a	$710.7K
Total assets	$1.55M	$1.35M	$1.31M	$2.08M
Total liabilities	$4.95M	$22.10M	$7.69M	$1.35M
Shareholders' equity	-$3.40M	-$20.75M	-$6.38M	$733.2K
Return on year-end equity	n/a	n/a	n/a	n/m
Shares outstanding	16.07M	230.21M	3.53M	4.26M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Accustem Sciences Inc.	Semnur Pharmaceuticals, Inc.	Aspire Biopharma Holdings, Inc.	Alzamend Neuro, Inc.
Latest	n/a	n/a	$6.2K Ended 2025-12-31	n/a
1 year earlier	n/a	n/a	n/a	n/a
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a